<table>
<thead>
<tr>
<th>Porcine Pathogens</th>
<th>ISU VDL in 2007</th>
<th>MIC Susceptibility Profile of Porcine Pathogens Submitted to ISU VDL in 2007</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of Isolates</strong></td>
<td><strong>A suis</strong></td>
<td><strong>APP</strong></td>
</tr>
<tr>
<td>347</td>
<td>183</td>
<td>63</td>
</tr>
</tbody>
</table>

| **Percent Susceptible*** | **Ampicillin** | **Ceftiofur** | **Chlorotetracycline** | **Clindamycin** | **Danofoxacin** | **Enrofloxacin** | **Erythromycin** | **Florfenicol** | **Gentamicin** | **Neomycin** | **Oxytetracycline** | **Penicillin** | **Spectinomycin** | **Sulfachloropyridazine** | **Sulfadimethoxine** | **Sulphathiazole** | **Tiamulin** | **Tilmicosin** | **Trimethoprim / Sulphamethoxazole** | **Tulathromycin** | **Key:** |
|-------------------------|---------------|---------------|------------------------|-----------------|----------------|---------------|---------------|----------------|-----------------|---------------|-----------------|---------------|----------------|-----------------|----------------|----------------|-------------|----------------|-----------------|----------------|----------------|----------------|
| **Ampicillin** | 94% | 86% | 33% | 34% | 100% | 26% | 99% | 98% | 98% | 98% | 34% | 99% | 14% |
| **Ceftiofur** | 99% | 99% | 67% | 100% | 59% | 99% | 100% | 100% | 98% | 99% | 89% |
| **Chlorotetracycline** | 91% | 57% | 100% | 6% | 30% | 6% | 99% | 96% | 96% | 24% | 14% | 6% |
| **Clindamycin** | 0% | 0% | 0% | 0% | 70% | 0% | 2% | 0% | 0% | 0% | 21% | 100% |
| **Danofoxacin** | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 100% |
| **Enrofloxacin** | 100% | 99% | 97% | 98% | 100% | 100% | 100% | 100% | 100% | 100% | 98% | 0% |
| **Erythromycin** | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 11% | 3% | 3% | 0% | 23% | 3% |
| **Florfenicol** | 100% | 97% | 78% | 7% | 0% | 14% | 100% | 100% | 100% | 94% | 100% | 84% |
| **Gentamicin** | 98% | 10% | 100% | 75% | 0% | 66% | 98% | 99% | 99% | 99% | 98% | 81% |
| **Neomycin** | 85% | 7% | 100% | 63% | 10% | 55% | 85% | 92% | 92% | 99% | 65% | 6% |
| **Oxytetracycline** | 58% | 8% | 100% | 5% | 30% | 4% | 91% | 64% | 64% | 24% | 5% | 0% |
| **Penicillin** | 1% | 4% | 0% | 0% | 100% | 0% | 10% | 92% | 92% | 0% | 91% | 0% |
| **Spectinomycin** | 0% | 14% | 0% | 0% | 90% | 0% | 83% | 1% | 1% | 0% | 23% | 1% |
| **Sulfachloropyridazine** | 100% | 88% | 0% | 35% | 0% | 21% | 89% | 37% | 37% | 23% | 58% | 0% |
| **Sulfadimethoxine** | 89% | 68% | 5% | 24% | 10% | 14% | 62% | 42% | 42% | 17% | 53% | 1% |
| **Sulphathiazole** | 88% | 63% | 0% | 35% | 0% | 14% | 59% | 33% | 33% | 23% | 62% | 0% |
| **Tiamulin** | 2% | 97% | 0% | 0% | 100% | 0% | 84% | 1% | 1% | 0% | 93% | 0% |
| **Tilmicosin** | 85% | 96% | 25% | 0% | 70% | 0% | 92% | 22% | 22% | 0% | 22% | 84% |
| **Trimethoprim / Sulphamethoxazole** | 98% | 9% | 63% | 73% | 30% | 78% | 97% | 6% | 6% | 100% | 98% | 0% |
| **Tulathromycin** | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |

**Key:**
- **A suis** = Actinobacillus suis
- **APP** = Actinobacillus pleuropneumoniae
- **B bron** = Bordetella bronchiseptica
- **Non E coli** = non hemolytic E. coli
- **Erys** = Erysipelothrix
- **H ecoli** = hemolytic E. coli
- **HPS** = Haemophilus parasuis
- **P mul A** = Pasteurella multocida Type A
- **P mul D** = Pasteurella multocida Type D
- **S chol** = Salmonella choleraesuis
- **S suis** = Streptococcus suis
- **S typh** = Salmonella typhimurium

* In vitro antimicrobial test results do not represent therapeutic recommendations from the VDL or personnel therein. Extra/Off label usage of an antimicrobial which is limited/prohibited for certain species may result in legal action by FDA-CVM.

** These are the only antimicrobials with valid breakpoints correlated with clinical outcome in species presented.

*** Percent of isolates with a susceptible value.

**** Methicillin resistant is represented by oxacillin.

ND Not done